Deutsche Bank
RAPP

Deutsche Bank’s Rapport Therapeutics RAPP Stock Holding History

Deutsche Bank’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Buy
32,212
+8,043
+33% +$296K ﹤0.01% 2150
2026
Q1 		$756K Buy
24,169
+2,634
+12% +$74.1K ﹤0.01% 2351
2025
Q4 		$653K Buy
21,535
+15,286
+245% +$423K ﹤0.01% 2426
2025
Q3 		$186K Hold
6,249
– – ﹤0.01% 3099
2025
Q2 		$71.1K Sell
6,249
-253
-4% -$2.69K ﹤0.01% 3361
2025
Q1 		$65.2K Buy
6,502
+4,185
+181% +$54.3K ﹤0.01% 3316
2024
Q4 		$41.1K Buy
+2,317
New +$51.3K ﹤0.01% 3445

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Deutsche Bank's RAPP Position: Q2 2026 in Review

Deutsche Bank increased its Rapport Therapeutics (RAPP) stake by 33% in Q2 2026, buying an estimated $296K and bringing the position to 32,212 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #2150.

Deutsche Bank first reported a position in RAPP in Q4 2024 and has held it in 7 quarters since. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Deutsche Bank held 32,212 shares of Rapport Therapeutics worth $1.34M as of Q2 2026.
  • Deutsche Bank bought 8,043 Rapport Therapeutics shares in Q2 2026, an estimated $296K.
  • Rapport Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #2150 holding.
  • Deutsche Bank first reported a position in Rapport Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.